Comparative Effectiveness of Empagliflozin and Dapagliflozin in Chinese Patients with Type 2 Diabetes Mellitus.

IF 0.9 Q4 PHARMACOLOGY & PHARMACY

Hospital Pharmacy Pub Date : 2025-12-12 DOI:10.1177/00185787251392803

Pan-Pan Zheng, Ya-Nan Zhao, Meng Du, Jing-Hua Sun, Zhe Zhao, Jing-Tao Liu, Li-Li Zhang, Zan-Chao Liu, Xian Xiu

{"title":"Comparative Effectiveness of Empagliflozin and Dapagliflozin in Chinese Patients with Type 2 Diabetes Mellitus.","authors":"Pan-Pan Zheng, Ya-Nan Zhao, Meng Du, Jing-Hua Sun, Zhe Zhao, Jing-Tao Liu, Li-Li Zhang, Zan-Chao Liu, Xian Xiu","doi":"10.1177/00185787251392803","DOIUrl":null,"url":null,"abstract":"Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become cornerstone drugs for the treatment of T2DM. Comprehensive direct comparisons between the effects of different SGLT2 inhibitors are rare in Chinese studies. We aimed to compare the effects of empaglifllozin (EMPA) and dapaglifllozin (DAPA) in Chinese patients with T2DM.Methods: The study used real-world data for retrospective analysis. The hospitalized patients treated with EMPA or DAPA in our hospital between December 1, 2022 and October 31, 2024 were screened. The matching of 1:1 propensity score (PS) balanced the baseline of EMPA and DAPA groups. To compare the effects of EMPA and DAPA in T2DM patients.Results: The study retrospectively enrolled 5171 patients and finally screened 199 patients (EMPA group) and 179 patients (DAPA group). After 1:1 PS matching, 124 pairs were found successfully. The changes of HbAlc, FBG, HbAl, eAG, TG, TC, HDL-c, LDL-c, AST, ALT, TBiL, DBiL, eGFR and BUN, or the control rates of HbAlc < 7%, FBG < 7 mmol/L, FBG < 6.5 mmol/L, TG, TC, HDL-c, LDL-c, AST, ALT, eGFR, BUN between EMPA and DAPA groups were not significantly different (P > 0.05). There was no significant difference in the incidence of CHD, DN, DR, DPVD, DPN, thyroid nodule, osteoporosis, urinary tract infection, chronic gastritis and oral inflammatory diseases (P > 0.05). The DAPA group showed a significantly lower incidence of MAFLD compared to the EMPA group during the observation period (P < 0.01).Conclusions: DAPA and EMPA showed parallel effects on glycolipid metabolism, liver and kidney function.","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251392803"},"PeriodicalIF":0.9000,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12700776/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00185787251392803","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become cornerstone drugs for the treatment of T2DM. Comprehensive direct comparisons between the effects of different SGLT2 inhibitors are rare in Chinese studies. We aimed to compare the effects of empaglifllozin (EMPA) and dapaglifllozin (DAPA) in Chinese patients with T2DM.

Methods: The study used real-world data for retrospective analysis. The hospitalized patients treated with EMPA or DAPA in our hospital between December 1, 2022 and October 31, 2024 were screened. The matching of 1:1 propensity score (PS) balanced the baseline of EMPA and DAPA groups. To compare the effects of EMPA and DAPA in T2DM patients.

Results: The study retrospectively enrolled 5171 patients and finally screened 199 patients (EMPA group) and 179 patients (DAPA group). After 1:1 PS matching, 124 pairs were found successfully. The changes of HbAlc, FBG, HbAl, eAG, TG, TC, HDL-c, LDL-c, AST, ALT, TBiL, DBiL, eGFR and BUN, or the control rates of HbAlc < 7%, FBG < 7 mmol/L, FBG < 6.5 mmol/L, TG, TC, HDL-c, LDL-c, AST, ALT, eGFR, BUN between EMPA and DAPA groups were not significantly different (P > 0.05). There was no significant difference in the incidence of CHD, DN, DR, DPVD, DPN, thyroid nodule, osteoporosis, urinary tract infection, chronic gastritis and oral inflammatory diseases (P > 0.05). The DAPA group showed a significantly lower incidence of MAFLD compared to the EMPA group during the observation period (P < 0.01).

Conclusions: DAPA and EMPA showed parallel effects on glycolipid metabolism, liver and kidney function.

查看原文本刊更多论文

恩格列净与达格列净治疗2型糖尿病的疗效比较。

背景：钠-葡萄糖共转运体-2 （SGLT2）抑制剂已成为治疗T2DM的基础药物。综合直接比较不同SGLT2抑制剂的疗效在中国的研究中很少见。我们的目的是比较恩帕列氟净（EMPA）和达格列氟净（DAPA）在中国T2DM患者中的作用。方法：采用真实资料进行回顾性分析。筛选2022年12月1日至2024年10月31日在我院接受EMPA或DAPA治疗的住院患者。EMPA组和DAPA组以1:1的倾向性评分（PS）匹配平衡基线。比较EMPA和DAPA在T2DM患者中的作用。结果：本研究回顾性纳入5171例患者，最终筛选出199例（EMPA组）和179例（DAPA组）患者。经过1:1的PS匹配，成功找到124对。HbAlc、FBG、HbAl、eAG、TG、TC、HDL-c、LDL-c、AST、ALT、TBiL、DBiL、eGFR、BUN的变化，或HbAlc P控制率（0.05）。两组冠心病、DN、DR、DPVD、DPN、甲状腺结节、骨质疏松、尿路感染、慢性胃炎、口腔炎性疾病的发生率比较，差异均无统计学意义（P < 0.05）。在观察期内，DAPA组与EMPA组相比，MAFLD的发生率明显降低(P)。结论：DAPA与EMPA对糖脂代谢、肝肾功能的影响是平行的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hospital Pharmacy PHARMACOLOGY & PHARMACY-

CiteScore

1.70

自引率

0.00%

发文量

期刊介绍： Hospital Pharmacy is a monthly peer-reviewed journal that is read by pharmacists and other providers practicing in the inpatient and outpatient setting within hospitals, long-term care facilities, home care, and other health-system settings The Hospital Pharmacy Assistant Editor, Michael R. Cohen, RPh, MS, DSc, FASHP, is author of a Medication Error Report Analysis and founder of The Institute for Safe Medication Practices (ISMP), a nonprofit organization that provides education about adverse drug events and their prevention.